The mechanism of non-blocking inhibition of sodium channels revealed by conformation-selective photolabeling

Mátys C. Földi1,2 | Krisztina Pesti1,3,4 | Katalin Zboray2 | Adam V. Toth2 | Tamás Hégedüs5 | András Málnási-Csizmadia6 | Peter Lukacs1,2 | Arpad Mike1,2,3

1MTA-ELTE NAP B Opto-Neuropharmacology Group, Budapest, Hungary
2Plant Protection Institute, Centre for Agricultural Research, Martonvásár, Hungary
3Department of Biochemistry, Eötvös Loránd University, Budapest, Hungary
4School of PhD Studies, Semmelweis University, Budapest, Hungary
5Department of Diophysics and Radiation Biology, Semmelweis University, Budapest, Hungary
6Motor Pharmacology Research Group, Department of Biochemistry, Eötvös Loránd University, Budapest, Hungary

Correspondence
Arpad Mike, MTA-ELTE NAP B Opto-Neuropharmacology Group, Budapest, Hungary.
Email: arpadmike1@gmail.com

Funding information
Hungarian Brain Research Program, Grant/Award Number: KTIA-NAP-13-2-2014-002; Hungary’s Economic Development and Innovation Operative Programme, Grant/Award Number: GINOP-2.3.2-15-2016-00051; NKFIH, Grant/Award Number: K127961; Semmelweis Science and Innovation Fund

Background and Purpose: Sodium channel inhibitors can be used to treat hyperexcitability-related diseases, including epilepsies, pain syndromes, neuromuscular disorders and cardiac arrhythmias. The applicability of these drugs is limited by their nonspecific effect on physiological function. They act mainly by sodium channel block and in addition by modulation of channel kinetics. While channel block inhibits healthy and pathological tissue equally, modulation can preferentially inhibit pathological activity. An ideal drug designed to target the sodium channels of pathological tissue would act predominantly by modulation. Thus far, no such drug has been described.

Experimental Approach: Patch-clamp experiments with ultra-fast solution exchange and photolabeling-coupled electrophysiology were applied to describe the unique mechanism of riluzole on Nav1.4 sodium channels. In silico docking experiments were used to study the molecular details of binding.

Key Results: We present evidence that riluzole acts predominantly by non-blocking modulation. We propose that, being a relatively small molecule, riluzole is able to stay bound to the binding site, but nonetheless stay off the conduction pathway, by residing in one of the fenestrations. We demonstrate how this mechanism can be recognized.

Conclusions and Implications: Our results identify riluzole as the prototype of this new class of sodium channel inhibitors. Drugs of this class are expected to selectively prevent hyperexcitability, while having minimal effect on cells firing at a normal rate from a normal resting potential.

KEYWORDS
arrhythmias, binding sites, epilepsy, local anaesthetics, pain, riluzole, sodium channels

Abbreviations: NaV1.4, voltage gated sodium 1.4 channel; NaV1.2, voltage gated sodium 1.2 channel; NaV1.5, voltage gated sodium 1.5 channel; SSI, steady-state inactivation protocol; RFI, recovery from inactivation protocol; SDO, state-dependent onset protocol; 3PT, three pulse train protocol.

Peter Lukacs and Arpad Mike should be considered joint senior authors.
1 | INTRODUCTION

Hyperexcitability is at the core of a rather diverse set of disorders affecting the heart, skeletal muscles and the nervous system. Out-of-control electric activity is involved in the development of several types of epilepsies, chronic pain syndromes, neuromuscular disorders, cardiac arrhythmias and even psychiatric disorders (Rogawski & Löscher, 2004). These conditions can originate from genetic conditions (mutations altering the operation of channels themselves or proteins involved in their modulation) or can be due to damages caused by mechanical injury, inflammation, or ischaemia.

To suppress hyperexcitability, sodium channels are the primary target because they are responsible for the fast onset of action potentials, as well as their all-or-none and self-regenerating nature.

Sodium channels have a pseudo-tetrameric structure, consisting of four homologous domains (D1 to D4). Each domain contains six transmembrane segments (S1 to S6), S1 to S4 of each domain form four voltage-sensor units at the peripheral region of the channel, while S5, S6 and a loop between the two (“pore loop”) of the four domains together form the central pore of the channel. The central pore has a relatively large water-filled cavity below the selectivity filter; sodium channel inhibitor drugs are thought to inhibit conduction by entering this cavity and blocking conduction. Two pathways are known for the drugs to enter: the “hydrophobic pathway” leads to the central cavity from the membrane phase, through “fenestrations”—small holes that connect the central cavity with the membrane phase. Drug molecules can also access the central cavity via the “hydrophilic pathway,” that leads from the intracellular space through the activation gate—this is passable only when the channel is in open conformation (Hille, 1977). From the fact that most sodium channel inhibitor can bind to inactivated channels and does not require channel opening, one can conclude that for drugs that have a neutral form (not permanently charged), the hydrophobic pathway is dominant. The inhibitor binding region of the central cavity is extremely conserved—practically identical in all nine isoforms of voltage gated sodium channels (Payandeh & Minor, 2015). For this reason, it has been very difficult to achieve significant isomselectivity among drugs acting on this drug binding site. The first human isoform where the structure was elucidated is NaV1.4 (Pan et al., 2018), the major sodium channel isoform of skeletal muscle, where it plays a key role in action potential initiation and propagation. The published structure of this isoform provided the necessary background for our in silico studies. However, the effect of riluzole was not specific to this isoform. In cells expressing the neuronal NaV1.2, or the cardiac NaV1.5 isoforms, we observed that both the mechanism of action and the potency of riluzole were very similar (data not shown). We found that riluzole showed less than threfold difference in potency between isoforms, but a roughly hundredfold difference in potency between different activity patterns of the same isoform (e.g. different firing frequencies or different resting membrane potentials). This phenomenon has been called functional selectivity (Bagal et al., 2013; Sun et al., 2014) and it is essential for selective inhibition of pathological cells.

What is already known
- Sodium channel inhibitors act by channel block.
- A photoreactive riluzole derivative, when made to bind covalently, was able to cause non-blocking modulation.

What this study adds
- Non-blocking modulation is the predominant mechanism of riluzole itself. This effect involves the F1579 residue.
- This mechanism enables riluzole to uniquely combine fast onset/offset kinetics with high affinity.

What is the clinical significance
- Non-blocking modulation is especially effective against hyperexcitability conditions and pathological high frequency firing.
- Compounds of this class may be superior anti-epileptics, analgesics, anti-arrhythmics or neuroprotectants.

Sodium channels are activated and inactivated within a few milliseconds. However, a small fraction (0.5 to 5%) of sodium channels evade rapid inactivation and produce a current component named persistent or late sodium current. This component plays a crucial role in the initiation of action potentials and its enlargement has been observed in several hyperexcitability-related pathologies (Cannon, 2018; Lampert et al., 2006; Makielski, 2016; Meisler, 2019; Stafstrom, 2007; Tang et al., 2015; van Zundert et al., 2012).

In order to design therapeutically useful sodium channel inhibitors, one encounters the seemingly impossible task of having to prevent pathological hyperexcitability, while maintaining the normal physiological activity of nerves and muscles. Interestingly, there are compounds, which are able to carry out this feat—at least to a certain extent. These compounds include anti-arrhythmic, anti-epileptic, anti-spastic drugs. The trick that enables them to do so is state-dependence, that is, their preference for certain conformational states of the channel protein. Most sodium channel inhibitors prefer inactivated state to resting state and they bind to it more rapidly and/or dissociate from it more slowly. The fact that an inhibitor has a higher affinity to the inactivated state means that drug-bound inactivated channels form an energetically favourable complex. This implies both slower dissociation of the ligand from this conformation and slower recovery from inactivated to resting state. The latter effect—called modulation of channel gating—is an inseparable element of state-dependent inhibition, as described by the modulated receptor hypothesis (Hille, 1977). High affinity to inactivated state ensures delayed dissociation, while modulation ensures delayed conformational transition to the low affinity resting state, thus restraining both
possible pathways to recovery (dissociation followed by recovery or recovery followed by dissociation).

Pathological states induced by injury, inflammation, ischaemia, tumour or epilepsy alter the electrical characteristics of excitable cells, which may include a depolarized membrane potential due to energy failure, increased leakage currents, left-shifted voltage sensitivity of sodium channels and increased persistent component of the sodium current (Fischer et al., 2017; Hammarström & Gage, 2002; Ma et al., 2006; Morris & Joos, 2016; Zhang et al., 2019; Zheng et al., 2012). These changes make sodium channels more likely to be in open and inactivated conformations. Therefore state-selectivity alone is enough for preferential inhibition of pathological tissue. On a first impression, one could suppose that the stronger the state-preference is, the better the drug will be.

However, the temporal aspect must also be considered. Action potentials are fired repetitively and pathological behaviour of neurons is often manifested as high-frequency firing. The extent of state-dependence is, therefore, not the only crucial aspect, equally important is the onset/offset dynamics of state-dependent binding. Its significance is obvious in the case of Class 1 anti-arrhythmics, where subclasses a, b and c differ in their association/dissociation kinetics, but the same is true for the much higher firing rates in central and peripheral neurons. For selective inhibition of cells firing at pathologically high frequency, the ideal drug should work as a low pass filter, with a steep frequency response, to be able to distinguish pathological and physiological rates of firing. This, however, presents a theoretical limit for state-dependent binding, because fast dissociation precludes high affinity. One would want both fast binding/unbinding dynamics and high state dependence. However, high state-dependence requires high affinity to inactivated state and high affinity means slow dissociation, which means that binding/unbinding dynamics cannot be fast.

Intriguingly, riluzole seems to be able to elude this limitation. Here, we examine how this is possible.

We first describe the peculiar pattern of inhibition and we observed during and after riluzole perfusion. We use a voltage-clamp protocol where block and modulation of the channels are monitored in parallel. Paradoxically, two distinct recovery processes seem to coexist, with rates differing by more than two orders of magnitude. We presume that this peculiarity may be the key to being able to feature fast kinetics and high affinity at the same time. A fast recovery allows channels to regain their ability to conduct ions within ~10 ms. In spite of their ability to conduct, however, channels remain modulated by the drug for a much longer time: it requires ~2 s for the channels to recover from the modulatory influence. This mechanism enables riluzole to function as a low pass filter with an exceptionally steep frequency response, which is probably a key element of its distinctive therapeutic efficacy.

We set out to identify the physical processes that underlie fast and slow recovery processes with the help of conformation-selective photolabeling-coupled electrophysiology and in silico docking experiments.

2 | METHODS

In the experimental design and analysis, recommendations set out in BJP editorials were followed where they are relevant.

2.1 | Cell culture and expression of recombinant sodium channels

Cloning of the wild type and F1579A mutant rNaV1.4 channel constructs was performed as described previously (Lukacs et al., 2018).

Recombinant sodium channel-expressing cell lines were generated by transfection of wild type and F1579A mutant NaV1.4 BAC DNA constructs into HEK 293 cells (ATCC Cat# CRL-1573, RRID: CVCL_0045) by Fugene HD (Promega, Fitchburg, WI) transfection reagent according to the manufacturer's recommendations. Cell clones with stable vector DNA integration were selected by the addition of Geneticin (Life Technologies, Carlsbad, CA) antibiotic to the culture media (400 mg·mL⁻¹) for 14 days. HEK293 cells were maintained in DMEM, high glucose supplemented with 10% v/v FBS, 100 U·mL⁻¹ of penicillin/streptomycin and 0.4 mg·mL⁻¹ Geneticin (Life Technologies, Carlsbad, CA). For experiments cells were plated onto 35-mm Petri dishes or T75 flasks and cultured for 24–36 h. For manual patch-clamp experiments, Petri dishes were transferred to the recording chamber, where cells were kept under continuous flow of extracellular solution. For Port-a-Patch experiments, cells were dissociated from the dish with trypsin–EDTA, centrifuged and suspended into the extracellular solution.

2.2 | Electrophysiology

The composition of solutions (in mM) was as follows:- intracellular solution: 50 CsCl, 10 NaCl, 60 CsF, 20 EGTA, 10 HEPES, pH 7.2 (adjusted with 1-M CsOH); extracellular solution: 140 NaCl, 4 KCl, 1 MgCl₂, 2 CaCl₂, 5 c-glucose and 10 HEPES, pH 7.4 (adjusted with 1-M NaOH). The osmolality of intracellular and extracellular solutions was set to ~290 and ~300 mOsm, respectively. Data were sampled at 20 kHz and filtered at 10 kHz. Experiments were carried out at room temperature.

In manual patch-clamp experiments, whole-cell currents were recorded using an Axopatch 200B amplifier and the pClamp (RRID: SCR_011323) software (Molecular Devices, San Jose, CA). Pipette resistance ranged between 1.5 and 4.0 MΩ. Solution exchange was performed by the “liquid filament switch” method (Franke et al., 1987; Jonas, 1995), using a Burleigh LSS-3200 ultrafast solution switching system, as described in detail previously (Pestl et al., 2014). The flow rate was set using a DAD-12 solution exchange system (ALA Scientific Instruments Inc., Farmingdale, NY), to 0.2–0.3 ml·min⁻¹, which corresponded to 5–20 cm·s⁻¹ velocity. Ten to 90% solution exchange rates were between 1 and 3 ms.

In experiments with the Port-a-Patch system (Nanion, Munich, Germany), currents were recorded using an EPC10 plus amplifier and...
the PatchMaster software (HEKA Electronic, Lambrecht, Germany, RRID:SCR_000034). During cell catching, sealing and whole-cell formation, the PatchControl software (Nanion) commanded the amplifier and the pressure control unit. The resistance of borosilicate chips was 2.0–3.5 MΩ.

2.3 Voltage protocols

The “steady-state inactivation” (SSI) protocol investigated the availability of channels at different membrane potentials, the “recovery from inactivation” (RFI) protocol investigated the dynamics of channels regaining their availability after inactivation and the state-dependent onset (SDO) protocol investigated the dynamics of developing inhibition. These same protocols have been used before (Lukacs et al., 2018); and they are illustrated in Figure 5a.

The “three pulse train” (3PT) protocol (Figure 2a,d) was similar to the one we called by this name before (Lukacs et al., 2018); but in this study, it was optimized for maximal time resolution. The protocol is designed to monitor changes in both gating kinetics and gating equilibrium. For the sake of high time resolution, it uses only a single interpulse interval, 2 ms (instead of several interpulse intervals as in RFI), and only a single membrane potential, −65 mV (instead of several membrane potentials as in the “steady-state inactivation” protocol—SSI). Thus, we could record changes at 26-ms resolution (38.5 Hz). In each experiment, we delivered 100 consecutive trains: after six initial control trains, we perfused riluzole throughout 10 trains (i.e., for 260 ms) and then monitored washout for the remaining 84 trains. Perfusion was started and stopped during the 10-ms intervals between two trains, which was amply enough for complete exchange of the solution with the theta tube system.

Peak amplitudes of evoked currents have been determined after subtracting capacitive and leakage artefacts. Recordings from a typical cell throughout a 100-train experiment are shown in Figure 2b. The six control traces are shown in blue, the 10 traces recorded during riluzole perfusion are in red (dark to light red indicates consecutive traces) and currents evoked during washout are shown in light grey to black. Figure 2c illustrates the same currents after subtraction of artefacts. Figure 2d shows the same corrected current traces in sequential order, together with the voltage protocol, as they were evoked in the experiment (only the first 29 of the 100 trains, for the sake of clarity). Peak amplitudes are marked by circles: blue (first pulses), red (second pulses) and green (third pulses). Connecting blue, red and green circles, we get different onset and offset characteristics, as shown for n = 7 cells in Figure 2e. All amplitudes were normalized to the first pulse-evoked amplitude at the start of the experiment (first, second and third pulse-evoked amplitudes each to its own control, to help comparison of inhibited fractions). Current traces for the same seven cells, as well as for the nine recorded binding site mutant cells, are shown in Figure S1, together with a detailed discussion of fitted time constants.

A small fraction of channels (11.4 ± 0.1% by the end of the 100th train) underwent slow inactivation during the test; this was a necessary trade-off for high temporal resolution. In order to appropriately calculate the extent of inhibition by riluzole, we corrected for the slow inactivated fraction: a sum of an exponential and a linear component was fit to the first 6 and last 3 points of first pulse-evoked current amplitudes in each cell (Figure S1B,H). This fitted function represented the non-slow-inactivated fraction f_{slow}(t) of the channel population. Measured amplitude plots (A_{slow}(t)) then were transformed into corrected amplitude plots (A_{corr}(t)) by expressing it as a fraction of non-slow-inactivated channels: A_{corr}(t) = A_{slow}(t)/f_{slow}(t). This is illustrated in Figure S1B,C, where panel C shows the same data as panel B, after correction. Measurement of the extent of inhibition and determination of onset and offset time constants were performed on the corrected plots.

2.4 UV photoactivation

The recording chamber of the Port-a-Patch was customized to accommodate a 400-μm diameter quartz optic fibre, which was placed 3–4 mm above the recorded cell. The original perfusion manifold was replaced by a custom manifold positioned to the side of the recording chamber opposite to the waste removal. Solution exchange was complete within 1–2 s. UV light pulses were delivered by a 310-nm fibre-coupled Mightex FCS-0310-000 LED (Mightex, Pleasanton, CA), with 40-μW intensity. Pulses were triggered by the PatchMaster software.

2.5 Combined voltage and illumination protocols

To perform photolabeling-coupled electrophysiology experiments, we used the photoreactive analogue of riluzole, azido-riluzole (Lukacs et al., 2018). During drug perfusion, we used one of three illumination protocols, to compare the possibility of binding to different conformations (Figure 5a). While one of the three protocols was repeated at 2.5 Hz (every 400 ms), 90-ms UV light pulses were applied within each cycle. The UV pulses were delivered either during hyperpolarizations (“resting-state-illumination”), during depolarizations (“inactivated-state-illumination”), or while cells were kept at the approximate half-inactivation voltage (“V-half-illumination”), that is, when channels were distributed roughly equally between the two conformations. Evoked current amplitudes were monitored throughout the pulsed illumination period. In the case of the V-half-illumination protocol, the long segment spent at −65 mV allowed us to monitor changes in gating equilibrium by comparing first pulse-evoked and third pulse-evoked amplitudes. The second pulse was introduced to monitor changes in gating kinetics as well, as we have discussed in the case of the 3PT protocol. To each cell, a maximum of 450 UV pulses was delivered (i.e., for up to 3 min), it was stopped earlier whenever evoked currents were inhibited to ~20% of their original amplitude. (Note that an 80% inhibition did not mean an 80% occupancy of binding sites, as we will discuss below.) Gating kinetics and equilibrium of the channels were investigated both before drug perfusion and after washout, using the “recovery from
inactivation” (RFI), “steady-state inactivation” (SSI) and “state-dependent onset” (SDO) voltage protocols.

Variations in the combined voltage and illumination protocols provided further insight in the mechanism, regarding the relative contribution of modulation and channel block (Figure S2) and regarding the sequence of recovery from inactivation and unbinding (Figure S3).

2.6 Data analysis

Curve fitting was done in Microsoft Excel (RRID:SCR_016137), using the Solver Add-in. Steady-state inactivation (SSI) curves were fitted using the Boltzmann function: \( I = I_{\text{max}} /[1 + \exp(V_p - V_{1/2}/-k)] \), where \( V_p \) is the pre-pulse potential, \( V_{1/2} \) is the voltage where the curve reached its midpoint and \( k \) is the slope factor.

Recovery from inactivation (RFI) experiments were fitted by mono- or bi-exponential function: \( I = A_1 * [1 - \exp(-t_{\text{p}}/\tau_1)] + A_2 * [1 - \exp(-t_{\text{p}}/\tau_2)] \), where \( \tau_1 \) and \( \tau_2 \) are the fast and slow time constants, \( A_1 \) and \( A_2 \) are their contributions to the amplitude (\( A_2 = 0 \), for monoexponential fitting) and \( t_{\text{p}} \) is the duration of the interpulse interval. We observed that recovery (not only in control, but in the presence of riluzole, and with covalently bound azido-riluzole as well) was steeper than a simple exponential function; therefore, we introduced the exponent \( x \). When its value was unconstrained, best fits produced \( x = 2.35 \pm 0.65 \) in control (range: 1.22 to 3.15) and \( x = 3.19 \pm 0.51 \) in the presence of 100-μM riluzole (range: 1.95 to 5.54). However, the value of the exponent affected the value of the time constant, as we have discussed before (Lukacs et al., 2018). For this reason, we chose \( x = 1.5 \), the minimal value that gave acceptable fits and used it for fitting throughout the experiments. Curve fitting was started by monoexponential fitting and the second exponential component was introduced only if the sum of squared differences improved by at least 10%.

State-dependent onset (SDO) data were fitted with either single or double exponential functions: \( I = A_1 * \exp(-t_{\text{p}}/\tau_1) + A_2 * \exp(-t_{\text{p}}/\tau_2) \), where \( A_1 \) and \( A_2 \) are the relative amplitudes of the two components and \( t_{\text{p}} \) is the duration of the pulse.

Averaging of SSI, RFI and SDO curves was not done by calculating the mean of measured points because this would introduce an error in the slope of curves. Instead, parameters from individually fitted experimental curves were averaged (arithmetic mean for amplitudes, membrane potential values and slope factors; geometric mean for time constants) and the curve was constructed using the averaged parameters.

Apparent affinity (IC50) values were calculated from either the extent of inhibition or from the onset and offset time constants. Apparent affinity (apparent \( K_d \)) has been used to describe different potency of the same concentration of inhibitor under different holding potentials (i.e., at different resting-inactivated equilibria) (Kuo & Bean, 1994; Lenkey et al., 2011). Here we extend its use to non-equilibrium conditions, where it represents the dynamically changing potency of sodium channel inhibitors during dynamically changing membrane potential. As we have seen for example in the 3PT protocol, the potency can change radically even on the submillisecond time scale, due to the interrelated dynamics of binding and gating. This fast dynamics of changes in potency cannot be monitored by obtaining conventional concentration response measurements. The advantage of using apparent affinity values is that they can be calculated from a single inhibition value, using the simplified Hill equation: when a one-to-one binding is assumed, the Hill equation is reduced to \( \ln h = cc/c( + IC_{50}) \), where \( lnh \) is the inhibited fraction and \( cc \) is the drug concentration. The calculation is most accurate at ~50% inhibition, but becomes increasingly inaccurate as inhibition approaches either 0 or 100%.

Apparent affinity can also be calculated from onset and offset time constants (obtained by single exponential fitting of amplitudes in the 3PT protocol), if we suppose a single-step binding reaction:

\[
\text{IC}_{50} = cc * t_{\text{on}}/(t_{\text{off}} - t_{\text{on}})
\]

In the case of riluzole, as we will discuss below, the inhibited fraction and the bound fraction were not equivalent; therefore, we expected that the IC50 values calculated by the two ways would differ (see Figure S1).

2.7 Statistics

The data and statistical analysis comply with the recommendations of the British Journal of Pharmacology on experimental design and analysis in pharmacology (Curtis et al., 2018). All values are given as mean ± SEM; \( n \) is the number of cells recorded from, we collected no technical replicates. Experiments with low seal resistance (<1 GΩ), high series resistance (>10 MΩ), or small currents (<1 nA) were excluded from analysis. Because seal resistance or series resistance occasionally changed during experiments, group sizes varied between \( n = 6 \) and \( n = 10 \). This presents no problem in statistical evaluation, since all post-treatment measurements were compared to pretreatment measurements in the same cell; therefore, groups were of equal sizes in all statistical tests. Data were tested for normality using Pearson’s chi-squared test. For the occasional non-normally distributed data, the Wilcoxon signed-rank test was used. For normally distributed data, drug effects were compared to control using the two-tailed, paired Student’s t-test. Normalization of amplitudes was done after statistical evaluation, only for the sake of making observed effects comparable. In statistical tests, \( P < 0.05 \) was considered significant.

2.8 Materials

All chemicals were obtained from Sigma-Aldrich. Azido-riluzole was synthesized by SONEAS Research Ltd., Budapest, Hungary.

2.9 Structural models and in silico docking

The human Nav1.4 (PDB ID: 6AGF) (Pan et al., 2018) was used, since in silico docking is more reliable to experimental structures than to homology models. The F1586A mutant structure was prepared.
manually by removing atoms of Phe and renaming the residue to Ala. The protein and riluzole (ZINC database ID: ZINC26671469) structures were prepared using prepare_ligand4.py and prepare_receptor4.py scripts from MGLTools with default options except hydrogens were added in the case of the protein (https://ccsb.scripps.edu/mgltools). Riluzole was docked to the wild type and F1586A mutant structures using AutoDock Vina (Trott & Olson, 2010). The search space was set up in PyMOL (The PyMOL Molecular Graphics System, Version 2.4, Schrödinger, LLC., RRID:SCR_000305) via the AutoDock/Vina plugin (Seeliger & de Groot, 2010) (Figure S4). The exhaustiveness option of Vina was set 128 instead of the default 8 for increasing the probability of finding the minimum of the scoring function. The num_modes and energy_range options were set to 100 and 20, respectively, to output a higher number of docked poses.

2.10 Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to corresponding entries in the IUPHAR/BPS Guide to PHARMACOLOGY http://www.guidetopharmacology.org and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 (Alexander et al., 2019).

3 RESULTS

3.1 Fast recovery in the presence of the drug

Results of the RFI experiment in control and in the presence of 100-μM riluzole are illustrated in Figure 1. In general, sodium channel inhibitor drugs are most effective at short hyperpolarizing gaps and their inhibitory effect gradually decreases with longer hyperpolarizations. This is conventionally explained by the progressive dissociation of drug molecules from resting state throughout the hyperpolarizing period because they have lower affinity to resting than to inactivated state. In the absence of any drug, at −130-mV channels recovered with a submillisecond time constant (τ1_recovery, in Table 1, first row). In the presence of 100-μM riluzole, recovery was delayed and it proceeded with a sixfold slower time constant (Table 1). Does this time constant indeed reflect dissociation?

3.2 Fast and slow recovery upon removal of the drug

We investigated the onset and offset kinetics using the 3PT protocol (Figure 2, see Section 2 for the details of the protocol). The offset of inhibition upon actual removal of the drug was more than hundredfold slower than recovery from inactivation in the presence of riluzole: it occurred with a time constant of 824 ± 99 ms (Figure 2f). Paradoxically, within each cycle, the recovery was almost complete within each 10 ms of between-trains hyperpolarization (see the minimal inhibition at blue traces), but then the inhibition was re-established before the second depolarization and became even stronger during the subsequent 8 ms spent near the V1/2 (−65 mV), causing a massive inhibition at the third pulse of each train. This pattern repeated itself during riluzole perfusion and also for 1–2 s after riluzole had been washed out.

The extent of inhibition in first, second and third pulse-evoked currents was 16.1 ± 4.0%, 73.4 ± 3.9% and 95.4 ± 1.2%. Apparent affinity (IC50) values can be determined from the extent of inhibition, as described in Section 2; these values corresponded with 606 ± 137, 33.5 ± 6.8 and 3.98 ± 1.32 μM, respectively. Mean ± SEM of time constants for the n = 7 cells are shown in Figure 2f.

In conclusion, two distinct recovery processes coexisted with completely different kinetics. Recovery is conventionally explained by dissociation, but the two recovery processes with more than hundredfold different time constants obviously cannot both reflect dissociation. To investigate what physical processes underlie the progression of both fast and slow recovery, we first studied the effect of mutating the most important residue of the local anaesthetic binding site, F1579. The presence of this aromatic residue is crucial in determining the affinity of binding (Mike & Lukacs, 2010; Zhang et al., 2015) and also in coupling drug binding to altered voltage sensor movements (Hanck et al., 2009; Muroi & Chanda, 2009), which is the basis of gating modulation.
**TABLE 1**  Essential results of experiments with riluzole and azido-riluzole

|                | Amplitude | SSI | RFI     |
|----------------|-----------|-----|---------|
|                | vs. Control | V<sub>1/2</sub> act | V<sub>1/2</sub> inact | τ<sub>1</sub> recovery |
| **Wild type**  |           |     |         |
| Control        | n = 9     | 0.59 ± 0.08 | 3.74 ± 0.44 |
| RIL MPC        | n = 7     | 0.90 ± 0.04 | 3.74 ± 0.44 |
| Control        | n = 7     | −24.9 ± 2.7 | −43.6 ± 3.90 |
| RIL            | n = 8     | −27.5 ± 2.6 | −68.9 ± 4.77 |
| Control        | n = 8     | −20.0 ± 2.0 | −37.9 ± 2.49 |
| ARIL - Resting-state-illum. | n = 7 | −35.2 ± 6.4 | −48.6 ± 3.08 |
| Control        | n = 7     | −26.1 ± 1.7 | −37.9 ± 4.53 |
| ARIL - V<sub>1/2</sub>-illum. | n = 10 | −27.6 ± 2.3 | −57.3 ± 5.58 |
| Control        | n = 10    | −25.4 ± 1.5 | −38.4 ± 1.64 |
| ARIL - Inact.-state-illum. | n = 7 | −23.5 ± 3.3 | −67.8 ± 2.86 |
| **F1579A mutant** |           |     |         |
| Control        | n = 7     | 0.48 ± 0.04 | 0.70 ± 0.03 |
| RIL MPC        | n = 7     | 0.94 ± 0.03 | 0.70 ± 0.03 |
| Control        | n = 7     | −26.6 ± 2.01 | −48.3 ± 2.30 |
| RIL            | n = 7     | −28.7 ± 1.96 | −58.9 ± 2.27 |
| Control        | n = 7     | −24.6 ± 4.5 | −52.4 ± 2.37 |
| ARIL - Resting-state-illum. | n = 6 | −32.3 ± 4.0 | −59.1 ± 1.93 |
| Control        | n = 6     | −31.6 ± 2.3 | −50.8 ± 2.74 |
| ARIL - V<sub>1/2</sub>-illum. | n = 7 | −30.9 ± 2.6 | −60.8 ± 2.12 |
| Control        | n = 7     | −28.3 ± 3.4 | −47.0 ± 2.67 |
| ARIL - Inact.-state-illum. | n = 7 | −24.8 ± 2.4 | −55.4 ± 2.17 |

Abbreviations: A<sub>1</sub> recovery, contribution of the fast time constant to the amplitude (the value of A<sub>2</sub> recovery is not shown because A<sub>2</sub> recovery = (1 − A<sub>1</sub> recovery); ARIL, 100-μM azido-riluzole; MPC, manual patch-clamp (for the rest of the data the Port-a-Patch instrument was used); RIL, 100-μM riluzole; SSI, RFI and SDO, voltage protocols (see Section 2); V<sub>1/2</sub> act, V<sub>1/2</sub> value of the activation curve; V<sub>1/2</sub> inact, V<sub>1/2</sub> value of the steady-state inactivation curve; τ<sub>1</sub> recovery and τ<sub>2</sub> recovery, fast and slow time constants of recovery; τ<sub>1</sub> onset, A<sub>1</sub> onset, τ<sub>2</sub> onset, A<sub>2</sub> onset, time constants and contributions to the inhibition of the fast and slow components of drug effect onset in the SDO protocol.

Note: Data obtained using the resting-state-, V-half- and inactivated-state-illumination protocols are highlighted by blue, teal and green shading. Black bold fonts indicate statistically significant effects and grey normal fonts indicate lack of significant difference between control and treatment.
|                | RFI | SDO |
|----------------|-----|-----|
|                | A₁ recovery | τ₂ recovery | τ₁ onset | A₁ onset | τ₂ onset | A₂ onset |
| Wild type      | 1   | 1   | 1.12 ± 0.34 | 0.08 ± 0.01 | 262 ± 47.0 | 0.20 ± 0.03 |
|                | 1   | 1   | 0.33 ± 0.05 | 0.87 ± 0.03 |          |          |
|                | 1   | 0.54 ± 0.25 | 0.09 ± 0.01 | 135 ± 55.3 | 0.15 ± 0.03 |
|                | 0.79 ± 0.04 | 8.43 ± 1.15 | 0.78 ± 0.25 | 0.16 ± 0.03 | 27.4 ± 13.0 | 0.34 ± 0.03 |
|                | 1   | 1.14 ± 0.52 | 0.11 ± 0.05 | 231 ± 165 | 0.27 ± 0.04 |
|                | 0.75 ± 0.07 | 129 ± 6.63 | 1.14 ± 0.21 | 0.38 ± 0.09 | 22.9 ± 17.7 | 0.31 ± 0.08 |
|                | 1   | 0.80 ± 0.36 | 0.09 ± 0.02 | 329 ± 102 | 0.32 ± 0.07 |
|                | 0.92 ± 0.04 | 135 ± 0.66 | 1.21 ± 0.12 | 0.62 ± 0.07 | 74.1 ± 17.9 | 0.23 ± 0.05 |
| F1579A mutant  | 0.91 ± 0.02 | 4.25 ± 1.77 |          |          |          |          |
|                | 0.84 ± 0.02 | 4.23 ± 1.31 |          |          |          |          |
|                | 0.90 ± 0.02 | 7.43 ± 1.24 | 1.74 ± 0.19 | 0.13 ± 0.01 | 247 ± 40.4 | 0.29 ± 0.04 |
|                | 0.92 ± 0.01 | 19.5 ± 2.64 | 1.78 ± 0.12 | 0.19 ± 0.02 | 210 ± 16.5 | 0.43 ± 0.05 |
|                | 0.82 ± 0.02 | 7.67 ± 1.37 | 3.06 ± 1.72 | 0.18 ± 0.03 | 172 ± 110 | 0.28 ± 0.05 |
|                | 0.80 ± 0.03 | 9.94 ± 2.01 | 2.06 ± 0.40 | 0.33 ± 0.03 | 129 ± 30.7 | 0.29 ± 0.03 |
|                | 0.90 ± 0.01 | 112 ± 2.03 | 3.96 ± 0.34 | 0.15 ± 0.02 | 477 ± 99 | 0.53 ± 0.06 |
|                | 0.81 ± 0.03 | 9.97 ± 2.20 | 2.66 ± 0.50 | 0.28 ± 0.05 | 296 ± 128 | 0.37 ± 0.04 |
|                | 0.91 ± 0.02 | 185 ± 2.07 | 2.62 ± 0.62 | 0.15 ± 0.01 | 251 ± 80.5 | 0.43 ± 0.07 |
|                | 0.84 ± 0.03 | 144 ± 3.74 | 2.03 ± 0.45 | 0.34 ± 0.02 | 305 ± 79.2 | 0.30 ± 0.05 |

Abbreviations: A₁ recovery, contribution of the fast time constant to the amplitude (the value of A₂ recovery is not shown because A₂ recovery = (1 − A₁ recovery); ARIL, 100-μM azido-riluzole; MPC, manual patch-clamp (for the rest of the data the Port-a-Patch instrument was used); RIL, 100-μM riluzole; SSI, RFI and SDO, voltage protocols (see Section 2); V₁/₂ act, the V₁/₂ value of the activation curve; V₁/₂ inact, the V₁/₂ value of the steady-state inactivation curve; τ₁ recovery and τ₂ recovery, fast and slow time constants of recovery; τ₁ onset, A₁ onset, τ₂ onset, A₂ onset, time constants and contributions to the inhibition of the fast and slow components of drug effect onset in the SDO protocol.

Note: Data obtained using the resting-state-, V-half- and inactivated-state-illumination protocols are highlighted by blue, teal and green shading. Black bold fonts indicate statistically significant effects and grey normal fonts indicate lack of significant difference between control and treatment.
The two recovery processes in binding site mutant channels

We repeated the same experiments using the RFI and 3PT protocols in cells expressing binding site mutant (F1579A) channels. We found that both the fast and the slow processes were radically altered by the mutation. In mutant channels, fitting the recovery required a biexponential function; see Table 1 for the time constants and their contribution to the amplitude. Riluzole only slightly delayed the major, fast component and had no significant effect on the minor, slow component (Table 1).

The effect of the mutation on the fast recovery was also indicated by the decreased inhibition of second pulse-evoked currents in the 3PT protocol (Figure 4); see the minimal difference between blue and red traces in Figure 4d. Interestingly, third pulse-evoked currents were still considerably inhibited (by 37.2 ± 6.6%). Apparent affinity (IC50) values, calculated from the extent of inhibition, were 1,590 ± 180, 895 ± 126 and 114 ± 20.0 μM for first, second and third pulse-evoked currents, respectively. Compared to the apparent affinity values of WT channels, first pulse-evoked responses were least sensitive to the mutation (2.62-fold decrease in affinity), while second and third pulse-evoked responses much more sensitive (26.7-fold and 28.6-fold decrease in affinity, respectively).

The slow recovery process was also accelerated (compare Figure 4c to Figure 2f). For a detailed analysis of time constants, see Figure S1.
3.4 | Conformation-selective photolabeling: the problem of interrelated binding and gating

To summarize, we observed two distinct recovery processes and they were both accelerated by mutation of the local anaesthetic binding site. What physical processes may underlie them?

In the presence of riluzole, the rate of the fast recovery process may be determined either by modulated gating (i.e. recovery from inactivation is slowed down by the bound drug) or by the dissociation of the drug—which is the conventional explanation.

The modulated receptor hypothesis (Hille, 1977) predicts that, since the drug has different affinities to different conformational states, drug binding must alter the energetics of conformational transitions, making higher affinity states more stable. Any mutation that changes binding affinities to different states must also change the effect of the drug on rates of transitions between these states (i.e. the gating of drug-bound channels). In other words, decreased affinity must necessarily cause decreased modulation of gating. Mutation-induced changes in the fast and slow recovery processes, therefore could both be manifestations of decreased affinity, on the level of gating and binding, respectively. Mutation-induced acceleration of the fast recovery process (compare Figure 1 and Figure 3) may be due to decreased modulation of channel gating, while acceleration of the slow recovery process (compare Figure 2f and Figure 4e) may be caused (at least partly) by faster ligand unbinding. If we accept this explanation, we must suppose that channel gating alone (without dissociation of the inhibitor) can make the channel available for activation and conduction. In other words, drug-bound channels can conduct, therefore “non-blocking modulation” (Lukacs et al., 2018) is possible.

The complex problem of interrelated gating and binding/unbinding can be simplified using photolabeling-coupled electrophysiology, as we have previously demonstrated (Lukacs et al., 2018). By binding the photoactive riluzole analogue, azido-riluzole, covalently to the channel, we could exclude the processes of binding and unbinding. We found that covalently bound channels were still able to conduct ions, but with modulated gating. In the 3PT protocol, modulated gating was reflected as the difference between first and second pulse-evoked currents (Figure 2). This difference almost disappeared when the key residue of the local anaesthetic binding site was mutated (Figure 4). It was logical to investigate if mutation of the same residue would cause the same lack of modulation in photolabeling-coupled electrophysiology experiments. In addition, we also investigated whether the binding was conformation-dependent. We have improved the method of photolabeling-coupled electrophysiology by synchronizing UV light pulses with the voltage protocol, instead of the continuous illumination we had used previously (Lukacs et al., 2018). This allowed us to target specific conformations of the channel and also to verify that the channel-ligand complex indeed assumes a drug-bound resting conformation before unbinding occurs. By precise timing of the UV light pulse, it was possible to test how soon this unfavourable drug-bound resting conformation was ended by unbinding (see supporting information). These data helped us identify the physical processes underlying both fast and slow recovery processes.

3.5 | State-dependence of binding

Riluzole, like most sodium channel inhibitors, is known to preferentially bind to inactivated channels (Catterall et al., 2019). We first intended to investigate how the conformation of the channel influences the ability of the drug to bind. We used the three voltage and illumination protocols as described in Section 2. Before drug perfusion and after washout, we assessed changes in gating kinetics and equilibrium of the channels by using the RFI, SSI and SDO voltage protocols. Values of the major gating parameters before and after treatment are summarized in Table 1. Covalent binding-induced changes in channel gating kinetics (RFI and SDO) and gating equilibrium (SSI) are shown in Figure 5b-d. Blue, teal and green colours indicate resting-state-, V-half- and inactivated-state-illumination, respectively. Insets show normalized data, where amplitudes were normalized to the maximal amplitude after azido-riluzole perfusion and irradiation. This gives a clearer picture of how the gating has been modulated. Similarly to our earlier data (Lukacs et al., 2018) obtained using continuous illumination, the population of ion channels that were still conducting showed modulated gating: delayed recovery from inactivation (Figure 5b), shifted steady-state availability (Figure 5c) and accelerated onset of inhibition (Figure 5d). Note that the SDO curves were also affected by covalently bound ligand (see Table 1): the fast time constants were not changed significantly, but their contribution increased. In the case of the inactivated-state-illumination protocol, the onset proceeded with a time constant of 1.21 ± 0.12 ms and its contribution increased from 8.8 ± 1.7% (control) to 61.6 ± 6.8%. The slow time constants were accelerated in all three illumination protocols. Since there was no possibility of binding or unbinding, these processes must
correspond with a conformational rearrangement of the ligand-channel complex.

Interestingly, 90-ms UV pulses delivered at every 400 ms during inactivated conformation were as effective as continuous illumination had been (Lukacs et al., 2018), in spite of the fact that the total illumination time was only 23.75% of it. It seems that repeatedly allowing azido-riluzole molecules to diffuse to their most favourable location (probably the binding site) without activating them and then delivering the UV pulse only when they are at the right location, actually works as effectively as continuous illumination.

In contrast, when UV pulses were delivered during resting state, no significant decrease of current amplitudes was observed and changes in recovery kinetics (RFI protocol) and equilibrium of inactivation (SSI protocol) were smaller (blue lines in Figure 5b–d; Table 1).
This may either suggest that the central cavity or the binding site itself is inaccessible at resting conformation or that the binding site has very low affinity at resting state. UV pulses delivered at the approximate half-inactivation voltage were between the other two illumination protocols in effectiveness.

3.6 The specificity of binding

Next, we investigated how specific the binding was, by testing the F1579A binding site mutant channels. We expected that if the binding was indeed specific, then we would see neither inhibition of the amplitude nor modulation of gating. Interestingly, mutation of the binding site did not prevent inhibition of the amplitude (provided that channels assumed inactivated conformation), but the modulation of gating was radically decreased (Figure 6a–c, Table 1). This suggests that when the high-affinity binding site is disrupted, inhibition is still possible, probably by binding to secondary binding sites, but these binding sites are less potent in conferring gating modulation. The involvement of this phenylalanine in the mechanism of modulation has been shown before (Ahern et al., 2008; Arcisio-Miranda et al., 2010; Hanck et al., 1994; Hanck et al., 2009; Liu et al., 2003; Muroi & Chanda, 2009); therefore, reduced modulation is not unexpected. However, the fact that mutant channels could still be effectively inhibited in inactivated state was indeed unexpected and it suggests the existence of one or more additional binding sites. Association to these lower affinity binding sites, which too were only available in the inactivated conformation, caused predominantly channel block and less modulation.

3.7 Possible location of bound riluzole

To gain insights into the possible binding sites of riluzole, we performed in silico docking of this small molecule to the wild type and mutant Nav1.4 structures. The human Nav1.4 (PDB ID: 6AGF) was used, since in silico docking is more reliable to experimental structures than to homology models. Importantly, riluzole binding was not observed in the pore region or close to the pore in the central cavity in either the wild type or the F1586A (F1579A in rNav1.4) structures (Figure 7). This inhibitor bound among transmembrane helices in three fenestrations of the wild type structure. In all cases, interactions involved the aromatic side chain of phenylalanine residues (F436, F1284 and F1586; which correspond to F430, F1277 and F1579 in rNav1.4), which are shown in Figure 7. In the absence of the phenylalanine side chain in the F1586A mutant, only two binding sites were observed at F436 and F1284. The main inference of the in silico docking data is that binding of riluzole within the fenestrations is sterically possible and energetically favourable. However, these are only predictions and must be validated by experimental data.
DISCUSSION

Our data suggest that riluzole is the first member of an entirely new class of sodium channel inhibitor chemicals. Its primary binding site is the well-characterized “local anaesthetic receptor,” with F1579 as the key residue. However, the location of the bound ligand is different from that of local anaesthetics and the effect exerted by it is also radically different. As for the location, in silico docking revealed that unlike other sodium channel inhibitor molecules, riluzole was preferentially located within the fenestrations and tended to avoid the central part of the pore or the vicinity of the selectivity filter, where it could interfere with conduction. Localization within the fenestration has been previously observed in molecular dynamics simulations investigating the general anaesthetic isoflurane (Raju et al., 2013) and propofol (Wang et al., 2018), as well as the local anaesthetic benzo-caine (Boiteux et al., 2014; Buyan et al., 2018; Martin & Corry, 2014) and lidocaine (neutral form) (Nguyen et al., 2019), but it has never been found to be the dominant position. The unusual location predicted by in silico docking is supported by the way riluzole acted in experiments. It stabilized inactivated conformation without interference with conduction. Inactivated state stabilization affected both the equilibrium and the recovery rate, as evidenced by the shift of the SSI and the RFI curves, respectively (Figure 1; see also Figure 1 in Lukacs et al., 2018).

Non-blocking modulation has been established as a valid mechanism for the covalently bound form of the photoreactive azido-riluzole in our previous study (Lukacs et al., 2018). However, this has not been shown as the predominant mechanism of riluzole and the involvement of specific binding to the local anaesthetic binding site also has not been demonstrated. In our current study, we have proven that this mechanism was not just an interesting theoretical possibility, but it is the major mechanism of this clinically used, exceptionally effective drug.

The non-instantaneous onset (as seen in the SDO protocol) and the delayed recovery (see the RFI protocol) together ensure that effective inhibition is confined within a strict temporal window. Single pulse-evoked currents or synaptic activity-evoked action potentials are “missed” by riluzole because inhibition becomes effective only after the channel has reached inactivated conformation and the conformation of the ligand-channel complex has been stabilized. After this, the inhibition is effective, but only for a limited time—even in the case of the non-therapeutic concentration of 100 μM, it was only effective for approximately 10–20 ms. At therapeutic concentrations, the effect of riluzole is no more than a fine modulation: the refractory time after an action potential is prolonged by a few milliseconds and a small fraction of the channel population is kept in inactivated conformation. The exact extent of prolongation and the magnitude of the fraction kept in inactivated conformation are dependent on the membrane potential during the interspike interval. This temporal window of effectiveness is the basis of both persistent (“late”) sodium current selectivity and the low pass filtering effect. The contribution of the persistent component of sodium currents (INaP) is significant during gradual depolarizations preceding action potentials, especially during burst firing (Del Negro et al., 2010; Taddese & Bean, 2002). In these cases, there is enough time for the onset of inhibition, and the inhibition remains effective until the membrane becomes hyperpolarized for a sufficient time.
An up-regulation of the persistent sodium current has been shown to be involved in a number of pathologies, including epilepsies (Oyrer et al., 2018; Stafstrom, 2007), cardiac pathologies (Antzelevitch et al., 2014; Chadda et al., 2017; Makielski, 2016), neurodegenerative disorders (van Zundert et al., 2012; Waxman, 2008), pain disorders (Lampert et al., 2006; Misawa et al., 2009; Xie et al., 2011), even cancer metastasis (Djamgoz & Onkal, 2013) and type II diabetes (Rizzetto et al., 2015). Selective inhibitors of $I_{\text{NaP}}$, including riluzole, have been found to be effective in cardiac diseases (Antzelevitch et al., 2014; Belardinelli et al., 2013; Karagueuzian et al., 2017), epilepsies (Anderson et al., 2014), pain syndromes (Xie et al., 2011) and neurodegenerative diseases. The classic anti-convulsant, phenytoin has been shown to selectively inhibit the persistent component and under certain conditions (e.g. after prolonged depolarizations), it was even more potent than ranolazine (Terragni et al., 2016). Interestingly, the mechanism of inhibition for the persistent (but not the transient) component of the current was proposed to be a modulation of the gating kinetics, not channel block (Colombo et al., 2013). This most likely contributes to its therapeutic efficacy. Riluzole was especially effective in preventing damage in spinal cord and peripheral nerve injury (Fehlings et al., 2016; Ghayour et al., 2017; Gloviczki et al., 2017). Its potential for other therapeutic indications are being intensively studied (Farinato et al., 2017). While other targets might contribute to its therapeutic effect (most importantly different potassium and calcium channels), sodium channel inhibition is its only verified effect in the submicromolar–low micromolar concentration range (Bellingham, 2011), which corresponds with its therapeutic plasma concentration (Lenkey et al., 2010).

Our data suggest that riluzole represents a new class among $I_{\text{NaP}}$ selective inhibitors because the non-blocking modulation mechanism endows it with an “ultrafast” offset kinetics, which, however, is not based on actual dissociation. A similar mechanism has been assumed for inhibition by riluzole in a recent computational study (Phillips & Rubin, 2019). To illustrate how this compares to offset kinetics of other well-known sodium channel inhibitors, we re-plotted the data from a comparative study of nine inhibitor compounds (El-Bizri et al., 2018), which included six anti-arrhythmic drugs and the three best known $I_{\text{NaP}}$ selective inhibitors. We supplemented these data with our results on the effects of riluzole (Figure 8). Binding rate constants were plotted against unbinding rate constants.
The latter were calculated from the time constants of the offset ($k_{off} = 1/\tau_{off}$), then the former was calculated from $k_{off}$ and the IC$_{50}$ value ($k_{on} = k_{off}/IC_{50}$). We calculated $k_{on}$ and $k_{off}$ values the same way for riluzole using time constants of both the fast and slow recovery processes (AMD, amiodarone; ELEC, eleclazine; FLC, flecaainide; LID, lidocaine; MEX, mexiletine; PRF, propafenone; QUI, quinidine; RIL, riluzole) and the IC$_{50}$ value 3.98 μM. As for the slow recovery process (which reflects true dissociation), riluzole did not differ from the other compounds, but when we used data from fast recovery process, it was in a completely different range. It seems that by staying in the fenestration, riluzole can “pretend” to have been dissociated, which practically increases its speed 366-fold. This allows it to be effective in frequency ranges that are unavailable for conventional drugs. If there was genuine dissociation during the fast recovery process, the value of $k_{on}$ would be 112 s$^{-1}$μM$^{-1}$. This would require an onset time constant of 0.086 ms at 100-μM concentration (from the equation $\tau_{on} = 1/(cc + k_{on} + k_{off})$), which is clearly much faster than the experimentally observed onset.

In summary, an ideal drug against hyperexcitability should be strongly state-dependent and at the same time show selective inhibition of high frequency firing. These two requirements, however, are difficult to reconcile. Strong state dependence requires high affinity to inactivated state and high affinity corresponds to slow dissociation. Slowly dissociating compounds, however, will not be selective for high-frequency firing. We found that there was a loophole in this argument and certain drugs can “exploit” that loophole. Small molecules may be able to “pretend” dissociation by “hiding” in one of the fenestrations. Riluzole is the first confirmed member of this presumed group of compounds. This drug has a unique collection of properties, which enable it to have improved therapeutic efficiency and fewer adverse effects. It can combine fast onset/offset kinetics with high affinity to the conventional local anaesthetic binding site. This high-affinity binding occurs only in depolarized (open or inactivated) conformations. The binding itself does not prevent conduction, only slightly alters the gating of channels, making them more likely to stay in inactivated conformation. This produces a preferential inhibition of (i) $I_{NaP}$, (ii) cells with depolarized membrane potential and (iii) cells firing at high frequencies. The combination of increased persistent component, compromised ability to keep resting membrane potential and abnormally high firing frequency almost always signifies pathology, which is the reason why riluzole can selectively inhibit this type of pathological activity. The basis of this selectivity is the non-blocking modulation mechanism. We anticipate that compounds of this class (fast-acting non-blocking modulators) may be favourable for the treatment of a number of pathologies, such as neuropathic pain syndromes, certain neuromuscular diseases, epilepsies and cardiac fibrillations, which are characterized by an enlarged persistent sodium current and high-frequency firing.

ACKNOWLEDGEMENTS
This work was supported by the Hungarian Brain Research Program (KTIA-NAP-13-2-2014-002), Hungary’s Economic Development and Innovation Operative Programme (GINOP-2.3.2-15-2016-00051), NKFIH K127961, and the Semmelweis Science and Innovation Fund.

AUTHOR CONTRIBUTIONS
A.M.-C., L.P., M.C.F. and M.A. designed research; P.K. performed manual patch-clamp experiments; M.C.F., L.P. and A.V.T. performed photolabeling-coupled electrophysiology experiments; H.T. performed molecular docking experiments; A.M.-C., L.P. and K.Z. contributed to the methodology and provided resources; M.C.F., P.K., L.P., H.T. and A.M. analysed data; M.C.F., L.P., H.T. and A.M. wrote the manuscript; all authors have read and approved the manuscript.

CONFLICT OF INTEREST
The authors declare no conflicts of interest.

DECLARATION OF TRANSPARENCY AND SCIENTIFIC RIGOUR
This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research as stated in the BJP guidelines for Design & Analysis and as recommended by funding agencies, publishers and other organisations engaged with supporting research.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Tamás Hegedűs https://orcid.org/0000-0002-5195-749X
Arpad Mike https://orcid.org/0000-0002-9095-8161
REFERENCES

Ahern, C. A., Eastwood, A. L., Dougherty, D. A., & Horn, R. (2008). Electrostatic contributions of aromatic residues in the local anesthetic receptor of voltage-gated sodium channels. *Circulation Research*, 102(1), 86–94. https://doi.org/10.1161/CIRCRESAHA.107.160663

Alexander, S. P. H., Mathie, A., Peters, J. A., Veale, E. L., Striessnig, J., Kelly, E., … CGTP Collaborators. (2019). The concise guide to pharmacology 2019/20: Ion channels. *British Journal of Pharmacology*, 176 (Suppl 1), S142–S228. https://doi.org/10.1093/bjp/bpz1479

Anderson, L. L., Thompson, C. H., Hawkins, N. A., Nath, R. D., Petersohn, A. N., Rajamani, S., … George, A. L. (2014). Antiepileptic activity of preferential inhibitors of persistent sodium current. *Epilepsia*, 55(8), 1274–1283. https://doi.org/10.1111/epi.12657

Antzelevitch, C., Nesterenko, V., Shryock, J. C., Rajamani, S., Song, Y., … Belardinelli, L. (2014). The role of late \( i_{\text{Na}} \) in development of cardiac arrhythmias. In P. C. Ruben (Ed.), *Voltage gated sodium channels* (Vol. 221, pp. 137–168). Berlin Heidelberg: Springer. https://doi.org/10.1007/978-3-642-41588-3_7

Arciso-Miranda, M., Muroy, Y., Chowdhury, S., & Chanda, B. (2010). Molecular mechanism of allosteric modification of voltage-dependent sodium channels by local anesthetics. *The Journal of General Physiology*, 136(5), 541–554. https://doi.org/10.1085/jgp.2010100438

Bagal, S. K., Brown, A. D., Cox, P. J., Omoto, K., Owen, R. M., Pryde, D. C., … Swain, N. A. (2013). Ion channels as therapeutic targets: A drug discovery perspective. *Journal of Medicinal Chemistry*, 56(3), 593–624. https://doi.org/10.1021/jm3011433

Belardinelli, L., Liu, G., Smith-Maxwell, C., Wang, W.-Q., El-Bizri, N., Hirakawa, R., … Shryock, J. C. (2013). A novel, potent, and selective inhibitor of cardiac late sodium current suppresses experimental arrhythmias. *Journal of Pharmacology and Experimental Therapeutics*, 344(1), 23–32. https://doi.org/10.1124/jpet.112.198887

Bellingham, M. C. (2011). A review of the neural mechanisms of action and clinical efficiency of riluzole in treating ALS. In B. Sakmann & E. Neher (Eds.), *Single-channel recording II: Updated and simplified guidance for analysis and their reporting II* (pp. 111–136). Amsterdam: Elsevier. https://doi.org/10.1016/B978-0-44-53613-6-00008-3

Djargoz, M. B. A., & Onkali, R. (2013). Persistent current blockers of voltage-gated sodium channels: A clinical opportunity for controlling metastatic disease. *Recent Patents on Anti-Cancer Drug Discovery*, 8(1), 66–84. https://doi.org/10.2174/17549281301017

El-Bizri, N., Xie, C., Liu, L., Limberis, J., Krause, M., Hirakawa, R., … Kahlig, K. M. (2018). Eclazine enhances selectivity for long QT syndrome type 3-associated late Na* current. *Heart Rhythm*, 15(2), 277–286. https://doi.org/10.1016/j.hrthm.2017.09.026

Farinato, A., Altamura, C., & Desaphy, J.-F. (2017). Effects of benzothiazolamines on voltage-gated sodium channels. *Handbook of Experimental Pharmacology*, 246, 233–250. https://doi.org/10.1007/164_2017_46

Fehlings, M. G., Nakashima, H., Nagoshi, N., Chow, D. S. L., Grossman, R. G., & Kopjar, B. (2016). Rationale, design and critical end points for the Riluzole in Acute Spinal Cord Injury Study (RISCIS): A randomized, double-blinded, placebo-controlled parallel multi-center trial. *Spinal Cord*, 54(1), 8–15. https://doi.org/10.1080/03043940.2015.95

Fischer, B. D., Ho, C., Kuzin, I., Bottaro, A., & O’Leary, M. E. (2017). Chronic exposure to tumor necrosis factor in vivo induces hyperalgesia, upregulates sodium channel gene expression and alters the cellular electrophysiology of dorsal root ganglion neurons. *Neuroscience Letters*, 653, 195–201. https://doi.org/10.1016/j.neulet.2017.05.004

Franke, C., Hatt, H., & Dudel, J. (1987). Liquid filament switch for ultra-fast exchanges of solutions at excised patches of synaptic membrane of crayfish muscle. *Neuroscience Letters*, 77(2), 199–204. https://doi.org/10.1016/0304-3940(87)90086-6

Ghayour, M. B., Abdolmaleki, A., & Behnam-Rassouli, M. (2017). The effect of riluzole on functional recovery of locomotion in the rat sciatic nerve crush model. *European Journal of Trauma and Emergency Surgery*, 43(5), 691–699. https://doi.org/10.1007/s00068-016-0691-4

Glovczki, B., Török, D. G., Márton, G., Gál, L., Bodzay, T., Pintér, S., … Karagueuzian, H. S., Pezhouman, A., Angelini, M., & Olcese, R. (2017). Benzothiazolamines on voltage-gated sodium channels: A clinical opportunity for controlling hyperalgesia, upregulates sodium channel gene expression and alters the cellular electrophysiology of dorsal root ganglion neurons. *Neuroscience Letters*, 653, 195–201. https://doi.org/10.1016/j.neulet.2017.05.004

Boiteux, C., Vorobyov, I., French, R. J., French, C., Yarov-Yarovoy, V., & Allen, T. W. (2014). Local anesthetic and antiepileptic drug access and binding to a bacterial voltage-gated sodium channel. *Proceedings of the National Academy of Sciences of the United States of America*, 111(36), 13057–13062. https://doi.org/10.1073/pnas.1408710111

Buyan, A., Sun, D., & Corry, B. (2018). Protonation state of inhibitors determines interaction sites within voltage-gated sodium channels. *Proceedings of the National Academy of Sciences of the United States of America*, 115(14), E3135–E3144. https://doi.org/10.1073/pnas.1714131115

Cannon, S. C. (2018). Sodium channelopathies of skeletal muscle. *Handbook of Experimental Pharmacology*, 246, 309–330. https://doi.org/10.1007/164_2017_52

Catterall, W. A., Leneau, M. J., & El-Din, T. M. G. (2019). Structure and pharmacology of voltage-gated sodium and calcium channels. *Annual Review of Pharmacology and Toxicology*, 60, 133–154. https://doi.org/10.1146/annurev-pharmtox-010818-021757

Chadda, K. R., Jeevaratnam, K., Lei, M., & Huang, C. L.-H. (2017). Sodium channel biophysics, late sodium current and genetic arrhythmic syndromes. *Pflügers Archiv - European Journal of Physiology*, 469(5–6), 629–641. https://doi.org/10.1007/s00424-017-1959-1

Colombo, E., Franceschetti, S., Avanzini, G., & Mantegazza, M. (2013). Phe- nytoin inhibits the persistent sodium current in neocortical neurons by modifying its inactivation properties. *PLoS ONE*, 8(1), e55329. https://doi.org/10.1371/journal.pone.0055329

Curtis, M. J., Alexander, S., Cirino, G., Dockerty, J. R., George, C. H., Giembycz, M. A., … Aihuvalia, A. (2018). Experimental design and analysis and their reporting II: Updated and simplified guidance for authors and peer reviewers: *Editorial. British Journal of Pharmacology*, 175(7), 987–993. https://doi.org/10.1111/bph.14153

Del Negro, C. A., Haynes, J. A., Pace, R. W., Brush, B. R., Teruyama, R., & Feldman, J. L. (2010). Synaptically activated burst-generating condu- tances may underlie a group-pacemaker mechanism for respiratory rhythm generation in mammals. In *Progress in brain research* (Vol. 187) (pp. 111–136). Amsterdam: Elsevier. https://doi.org/10.1016/B978-0-44-536313-6.00008-3

Jonas, P. (1995). Fast application of agonists to isolated membrane pat- ches. In B. Sakmann & E. Neher (Eds.), *Single-channel recording* (pp. 231–243). Boston, MA: Springer US. https://doi.org/10.1007/978-1-4419-1229-9_10

Karageuzian, H. S., Pezhouman, A., Angeliini, M., & Olcese, R. (2017). Enhanced late Na and Ca currents as effective antiarrhythmic drug.
targets. *Frontiers in Pharmacology*, 8(36), 1–17. https://doi.org/10.3389/fphar.2017.00036
Kuo, C. C., & Bean, B. P. (1994). Slow binding of phenytoin to inactivated sodium channels in rat hippocampal neurons. *Molecular Pharmacology*, 46(4), 716–725.
Lampert, A., Hains, B. C., & Waxman, S. G. (2006). Upregulation of persistent sodium current in dorsal horn neurons after spinal cord injury. *Experimental Brain Research*, 174(4), 660–666. https://doi.org/10.1007/s00221-006-0511-x
Lenkey, N., Karoly, R., Epresi, N., Vizi, E., & Mike, A. (2011). Binding of sodium channel inhibitors to hyperpolarized and depolarized conformations of the channel. *Neuropharmacology*, 60(1), 191–200. https://doi.org/10.1016/j.neuropharm.2010.08.005
Lenkey, N., Karoly, R., Lukacs, P., Vizi, E. S., Sunesen, M., Fodor, L., & Mike, A. (2010). Classification of drugs based on properties of sodium channel inhibition: A comparative automated patch-clamp study. *PLoS ONE*, 5(12), e15568. https://doi.org/10.1371/journal.pone.0015568
Liu, H., Atkins, J., & Kass, R. S. (2003). Common molecular determinants of flecainide and lidocaine block of heart Na+_ channels: Evidence from experiments with neutral and quaternary flecainide analogues. *The Journal of General Physiology*, 121(3), 199–214. https://doi.org/10.1085/jgp.200228723
Lukacs, P., Földi, M. C., Valánszki, L., Casanova, E., Biri-Kovács, B., Nytíray, L., ... Mike, A. (2018). Non-blocking modulation contributes to sodium channel inhibition by a covalently attached photo-reactive irizolue analog. *Scientific Reports*, 8(8110), 1–11. https://doi.org/10.1038/s41598-018-26444-y
Ma, C., Greenquist, K. W., & LaMotte, R. H. (2006). Inflammatory mediators enhance the excitability of chronically compressed dorsal root ganglion neurons. *Journal of Neurophysiology*, 95(4), 2098–2107. https://doi.org/10.1152/jn.00748.2005
Makiešliš, J. C. (2016). Late sodium current: A mechanism for angina, heart failure, and arrhythmia. *Trends in Cardiovascular Medicine*, 26(2), 115–122. https://doi.org/10.1016/j.tcm.2015.05.006
Martin, L. J., & Corry, B. (2014). Locating the route of entry and binding sites of benzocaine and phenytoin in a bacterial voltage gated sodium channel. *PLoS Computational Biology*, 10(7), e1003688. https://doi.org/10.1371/journal.pcbi.1003688
Meisler, M. H. (2019). SCN8A encephalopathy: Mechanisms and models. *Current Topics in Membranes*, 77, 133–143. https://doi.org/10.1016/bs.ctm.2016.06.001
Muroi, Y., & Chanda, B. (2009). Local anesthetics disrupt energetic coupling between the voltage-sensing segments of a sodium channel. *The Journal of General Physiology*, 133(1), 1–15. https://doi.org/10.1085/jgp.200810103
Nguyen, P. T., DeMarco, K. R., Vorobyov, L., Clancy, C. E., & Yarov-Yarovov, V. (2019). Structural basis for antiarrhythmic drug interactions with the human cardiac sodium channel. *Proceedings of the National Academy of Sciences of the United States of America*, 116(8), 2945–2954. https://doi.org/10.1073/pnas.1817446116
Oyser, J., Maljevic, S., Scheffer, I. E., Berkovic, S. F., Petroiu, S., & Reid, C. A. (2018). Ion channels in genetic epilepsy: From genes and mechanisms to disease-targeted therapies. *Pharmacological Reviews*, 70(1), 142–173. https://doi.org/10.1124/pr.117.014456
Pan, X., Li, Z., Zhou, Q., Shen, H., Wu, K., Huang, X., ... Yan, N. (2018). Structure of the human voltage-gated sodium channel Nav1.4 in complex with p1. *Science (New York, N.Y.)*, 362(6412), 1–9. https://doi.org/10.1126/science.aau2486
Payandeh, J., & Minor, D. L. (2015). Bacterial voltage-gated sodium channels (BacNaVs) from the soil, sea, and salt lakes enlighten molecular mechanisms of electrical signaling and pharmacology in the brain and heart. *Journal of Molecular Biology*, 427(1), 3–30. https://doi.org/10.1016/j.jmb.2014.08.010
Pesti, K., Szabo, A. K., Mike, A., & Vizi, E. S. (2014). Kinetic properties and open probability of α7 nicotinic acetylcholine receptors. *Neuropharmacology*, 81, 101–115. https://doi.org/10.1016/j.neuropharm.2014.01.034
Phillips, R. S., & Rubin, J. E. (2019). Effects of persistent sodium current blockade in respiratory circuits depend on the pharmacological mechanism of action and network dynamics. *PLoS Computational Biology*, 15(8), e1006938. https://doi.org/10.1371/journal.pcbi.1006938
Raju, S. G., Barber, A. F., LeBard, D. N., Klein, M. L., & Carnevale, V. (2013). Exploring volatile general anesthetic binding to a closed membrane-bound bacterial voltage-gated sodium channel via computation. *PLoS Computational Biology*, 9(6), e1003090. https://doi.org/10.1371/journal.pcbi.1003090
Rizzotto, R., Rocchetti, M., Sala, L., Ronchi, C., Villa, A., Ferrandi, M., ... Zaza, A. (2015). Late sodium current (INaL) in pancreatic β-cells. *Pflügers Archiv - European Journal of Physiology*, 467(8), 1757–1768. https://doi.org/10.1007/s00424-014-1613-0
Rogawski, M. A., & Löscher, W. (2004). The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. *Nature Medicine*, 10(7), 685–692. https://doi.org/10.1038/nm1074
Seeliger, D., & de Groot, B. L. (2010). Ligand docking and binding site analysis with PyMOL and Autodock/Vina. *Journal of Computer-Aided Molecular Design*, 24(5), 417–422. https://doi.org/10.1007/s10822-010-9352-6
Stafstrom, C. E. (2007). Persistent sodium current and its role in epilepsy. *Epilepsy Currents*, 7(1), 15–22. https://doi.org/10.1111/j.1535-7511.2007.00156.x
Surr, S., Cohen, J. C., & Dehnhardt, M. C. (2014). Inhibitors of voltage-gated sodium channel Na+ α 1.7: Patent applications since 2010. *Pharmaceutical Patent Analyst*, 3(5), 509–521. https://doi.org/10.4155/pa.14-39
Taddei, A., & Bean, B. P. (2002). Subthreshold sodium current from rapidly inactivating sodium channels drives spontaneous firing of tuberomammillary neurons. *Neuron*, 33(4), 587–600. https://doi.org/10.1016/S0896-6273(02)00574-3
Tang, Z., Chen, Z., Tang, B., & Jiang, H. (2015). Primary erythromelalgia: A review. *Orphanet Journal of Rare Diseases*, 10(127), 1–11. https://doi.org/10.1186/s13023-015-0347-1
Terragni, B., Scalmapi, P., Colombo, E., Franceschetti, S., & Mantegazza, M. (2016). Ranolazine vs phenytoin: Greater effect of ranolazine on the transient Na+ current than on the persistent Na+ current in central neurons. *Neuropharmacology*, 110, 223–236. https://doi.org/10.1016/j.jneuropharm.2016.06.029
Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. *Journal of Computational Chemistry*, 31(2), 455–461. https://doi.org/10.1002/jcc.21234
van Zundert, B., Izaurieta, P., Fritz, E., & Alvarez, F. J. (2012). Early pathogenesis in the adult-onset neurodegenerative disease amyotrophic lateral sclerosis. *Journal of Cellular Biochemistry*, 236. https://doi.org/10.1002/jcb.24234
Wang, Y., Yang, E., Wells, M. M., Bondarenko, V., Woll, K., Carnevale, V., ... Xu, Y. (2018). Propofol inhibits the voltage-gated sodium channel NaChBac at multiple sites. *The Journal of General Physiology*, 150(9), 1317–1331. https://doi.org/10.1085/jgp.201811993
Waxman, S. G. (2008). Mechanisms of disease: Sodium channels and neuroprotection in multiple sclerosis—Current status. *Nature Clinical Practice Neurology*, 4(3), 159–169. https://doi.org/10.1038/ncpneuro0735

Xie, R.-G., Zheng, D.-W., Xing, J.-L., Zhang, X.-J., Song, Y., Xie, Y.-B., … Hu, S.-J. (2011). Blockade of persistent sodium currents contributes to the riluzole-induced inhibition of spontaneous activity and oscillations in injured DRG neurons. *PLoS ONE*, 6(4), e18681. https://doi.org/10.1371/journal.pone.0018681

Zhang, H., Zou, B., Du, F., Xu, K., & Li, M. (2015). Reporting sodium channel activity using calcium flux: Pharmacological promiscuity of cardiac Nav1.5. *Molecular Pharmacology*, 87(2), 207–217. https://doi.org/10.1124/mol.114.094789

Zhang, Q., Ma, J.-H., Li, H., Wei, X.-H., Zheng, J., Li, G., … Wu, L. (2019). Increase in CO₂ levels by upregulating late sodium current is proarrhythmic in the heart. *Heart Rhythm*, 16(7), 1098–1106. https://doi.org/10.1016/j.hrthm.2019.01.029

Zheng, Q., Fang, D., Cai, J., Wan, Y., Han, J.-S., & Xing, G.-G. (2012). Enhanced excitability of small dorsal root ganglion neurons in rats with bone cancer pain. *Molecular Pain*, 8, 1744-8069-8–24. https://doi.org/10.1186/1744-8069-8-24

**SUPPORTING INFORMATION**
Additional supporting information may be found online in the Supporting Information section at the end of this article.

---

**How to cite this article**: Földi MC, Pesti K, Zboray K, et al. The mechanism of non-blocking inhibition of sodium channels revealed by conformation-selective photolabeling. *Br J Pharmacol*. 2021;178:1200–1217. https://doi.org/10.1111/bph.15365